{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:19:46Z","timestamp":1790108386824,"version":"4.0.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The College of Pharmacotherapy of Thailand","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"DOI":"10.13039\/501100002842","name":"Chiang Mai University","doi-asserted-by":"crossref","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100002842","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Based on the International Society for peritoneal dialysis (PD) recommendations, blockade of renin-angiotensin systems with an angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) improves residual kidney function in PD patients. However, the long-term effectiveness of ACEI\/ARB use in PD patients has not been fully elucidated. We, therefore, intend to perform a systematic review and meta-analysis to summarize the effects of ACEI\/ARB use on long-term mortality, cardiovascular outcomes, and adverse events among PD patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This systematic review will include both randomized controlled trials and non-randomized studies in adult PD patients. We also plan to incorporate data from our cohort study in Thai PD population into this review. We will search PubMed, Medline, EMBASE, Cochrane Library, Web of Science, Scopus, CINAHL, and grey literature from inception to February 29, 2019, with no language restrictions. The process of study screening, selection, data extraction, risk of bias assessment, and grading the strength of evidence will be performed independently by a pair of reviewers. Any discrepancy will be resolved through a team discussion and\/or consultation with the third reviewer. The pooled effects estimate and 95% confidence intervals will be estimated using DerSimonian-Laird random-effects models. Heterogeneity will be assessed by the Cochran Q test, <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup> index and tau-squared statistics. The funnel plots along with the Begg and Egger test and trim and fill method will be performed to investigate any evidence of publication bias. Preplanned subgroup analyses and random-effects univariate meta-regressions will be performed to quantify the potential sources of heterogeneity based on studies- and patient-characteristics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>This will be the first systematic review and meta-analysis to summarize the long-term effectiveness of renin-angiotensin system inhibitors in PD populations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>In summary, this systematic review and meta-analysis will summarize the effectiveness of ACEI\/ARB on long-term mortality, cardiovascular outcomes, and adverse events among adult PD patients by integrated all available evidences.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ethics and dissemination:<\/jats:title>\n            <jats:p>Based on the existing published data, an ethical approval is not required. The findings will be disseminated through scientific meetings and publications in peer-reviewed journals.<\/jats:p>\n            <jats:p>PROSPERO registration number: CRD42019129492.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000019767","type":"journal-article","created":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T05:52:45Z","timestamp":1587793965000},"page":"e19767","source":"Crossref","is-referenced-by-count":2,"title":["Effects of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on all-cause mortality, cardiovascular death, and cardiovascular events among peritoneal dialysis patients"],"prefix":"10.1097","volume":"99","author":[{"given":"Surapon","family":"Nochaiwong","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Care"},{"name":"Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy, Chiang Mai University, Chiang Mai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chidchanok","family":"Ruengorn","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care"},{"name":"Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy, Chiang Mai University, Chiang Mai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pajaree","family":"Mongkhon","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy, Chiang Mai University, Chiang Mai"},{"name":"Division of Pharmacy Practice, Department of Pharmaceutical Care, School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kednapa","family":"Thavorn","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy, Chiang Mai University, Chiang Mai"},{"name":"Ottawa Hospital Research Institute, Ottawa Hospital"},{"name":"Institute of Clinical and Evaluative Sciences, ICES uOttawa"},{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratanaporn","family":"Awiphan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care"},{"name":"Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy, Chiang Mai University, Chiang Mai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kajohnsak","family":"Noppakun","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy, Chiang Mai University, Chiang Mai"},{"name":"Department of Internal Medicine, Division of Nephrology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surachet","family":"Vongsanim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilaiwan","family":"Chongruksut","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy, Chiang Mai University, Chiang Mai"},{"name":"Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hutton","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa Hospital"},{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish M.","family":"Sood","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa Hospital"},{"name":"Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg A.","family":"Knoll","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa Hospital"},{"name":"Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,4]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ckj\/sfx149","article-title":"The European renal association - European dialysis and transplant association (ERA-EDTA) registry annual report 2015: a summary","volume":"11","author":"Kramer","year":"2018","journal-title":"Clin Kidney J"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrneph.2016.181","article-title":"Changes in the worldwide epidemiology of peritoneal dialysis","volume":"13","author":"Li","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"R3-20230915","first-page":"S411","article-title":"US. Renal Data System 2018 Annual Data, Report., Chapter 5:, Mortality","volume":"73","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1744-9987.2012.01144.x","article-title":"Cause-specific excess mortality among dialysis patients: comparison with the general population in Japan","volume":"17","author":"Wakasugi","year":"2013","journal-title":"Ther Apher Dial"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2215\/CJN.01750309","article-title":"Association of dialysis modality and cardiovascular mortality in incident dialysis patients","volume":"4","author":"Johnson","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/jama.2009.1488","article-title":"Cardiovascular and noncardiovascular mortality among patients starting dialysis","volume":"302","author":"de Jager","year":"2009","journal-title":"JAMA"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.kint.2019.03.015","article-title":"An international Delphi survey helped develop consensus-based core outcome domains for trials in peritoneal dialysis","volume":"96","author":"Manera","year":"2019","journal-title":"Kidney Int"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1681\/ASN.V12102158","article-title":"Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study","volume":"12","author":"Bargman","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1681\/ASN.V1351307","article-title":"Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial","volume":"13","author":"Paniagua","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0272-6386(03)00362-7","article-title":"The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2","volume":"41","author":"Termorshuizen","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/ndt\/gfp056","article-title":"Rate of decline of residual renal function is associated with all-cause mortality and technique failure in patients on long-term peritoneal dialysis","volume":"24","author":"Liao","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1046\/j.1523-1755.2002.00471.x","article-title":"A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients","volume":"62","author":"Wang","year":"2002","journal-title":"Kidney Int"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.jacc.2018.01.058","article-title":"Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use?","volume":"71","author":"Messerli","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00392-008-0668-3","article-title":"RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection","volume":"97","author":"Werner","year":"2008","journal-title":"Clin Res Cardiol"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/MNH.0000000000000484","article-title":"Renin-angiotensin system inhibition in advanced chronic kidney disease: how low can the kidney function go?","volume":"28","author":"Shah","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-139-2-200307150-00010","article-title":"Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study","volume":"139","author":"Li","year":"2003","journal-title":"Ann Intern Med"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1053\/j.ajkd.2004.01.019","article-title":"Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD","volume":"43","author":"Suzuki","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1440-1797.2009.01162.x","article-title":"Effect of renin-angiotensin system inhibitors on prevention of peritoneal fibrosis in peritoneal dialysis patients","volume":"15","author":"Jing","year":"2010","journal-title":"Nephrology (Carlton)"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"877","DOI":"10.6061\/clinics\/2012(08)04","article-title":"The effects of angiotensin-converting enzyme inhibitors on peritoneal protein loss and solute transport in peritoneal dialysis patients","volume":"67","author":"Basturk","year":"2012","journal-title":"Clinics (Sao Paulo)"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/ndt\/gfn421","article-title":"A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients","volume":"24","author":"Kolesnyk","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1177\/089686080702700413","article-title":"Impact of ACE inhibitors and AII receptor blockers on peritoneal membrane transport characteristics in long-term peritoneal dialysis patients","volume":"27","author":"Kolesnyk","year":"2007","journal-title":"Perit Dial Int"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"c31","DOI":"10.1159\/000210572","article-title":"Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis","volume":"112","author":"Shigenaga","year":"2009","journal-title":"Nephron Clin Pract"},{"key":"R24-20230915","first-page":"59","article-title":"A selective angiotensin receptor antagonist, Valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness","volume":"19","author":"Suzuki","year":"2003","journal-title":"Adv Perit Dial"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3747\/pdi.2014.00279","article-title":"ISPD cardiovascular and metabolic guidelines in adult peritoneal dialysis patients part I - assessment and management of various cardiovascular risk factors","volume":"35","author":"Wang","year":"2015","journal-title":"Perit Dial Int"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/089686080902900514","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peritoneal dialysis: systematic review and meta-analysis of randomized controlled trials","volume":"29","author":"Akbari","year":"2009","journal-title":"Perit Dial Int"},{"key":"R27-20230915","first-page":"CD009120","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients","author":"Zhang","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12882-017-0605-7","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials","volume":"18","author":"Liu","year":"2017","journal-title":"BMC Nephrol"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"19582","DOI":"10.1038\/s41598-019-55561-5","article-title":"Effectiveness of renin-angiotensin-aldosterone system blockade on residual kidney function and peritoneal membrane function in peritoneal dialysis patients: a network meta-analysis","volume":"9","author":"Phatthanasobhon","year":"2019","journal-title":"Sci Rep"},{"key":"R32-20230915","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"R33-20230915","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"(Pt A)","key":"R35-20230915","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-analysis in clinical trials revisited","volume":"45","author":"DerSimonian","year":"2015","journal-title":"Contemp Clin Trials"},{"key":"R36-20230915","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2288-7-5","article-title":"Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data","volume":"7","author":"Friedrich","year":"2007","journal-title":"BMC Med Res Methodol"},{"key":"R37-20230915","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R38-20230915","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"R39-20230915","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R40-20230915","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"R41-20230915","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R42-20230915","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"R43-20230915","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"R44-20230915","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrneph.2010.68","article-title":"Cardiovascular risk in the peritoneal dialysis patient","volume":"6","author":"Krediet","year":"2010","journal-title":"Nat Rev Nephrol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:11:19Z","timestamp":1694823079000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019767"}},"subtitle":["A protocol for systematic review"],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":41,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000019767","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}